Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
about
Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cellsComputational modelling of cancerous mutations in the EGFR/ERK signalling pathway.Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancerActivation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cellsCo-conserved features associated with cis regulation of ErbB tyrosine kinases.Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalizedEpidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.Ubiquitination-dependent regulation of signaling receptors in cancer.A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformationsThe tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signalingNexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.Pathways driving the endocytosis of mutant and wild-type EGFR in cancer.Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cellsPrediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiersDDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream EffectorsOncogenes come of age.Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerNeoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation.EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domainEffects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass SpectrometryCancer genes in lung cancer: racial disparities: are there any?Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceCollections of simultaneously altered genes as biomarkers of cancer cell drug responseComparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers.Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.Cellular functions regulated by phosphorylation of EGFR on Tyr845.Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Mutation of epidermal growth factor receptor is associated with MIG6 expression.Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
P2860
Q24337213-5151BB86-325D-414E-8002-0A4FD7C40438Q33508697-C18BB2FD-DE27-436E-928D-3ABB76486AA6Q33576845-B20A46A9-8B69-4CE3-8346-4717F6E00D3BQ33636907-2AA730DC-5BB8-4753-80B2-4F0EEAA81B25Q33778237-AC97D2EF-74EA-488A-B1B8-7B87A2735B27Q33779882-D211B8A7-4426-4DE7-9EA8-28213A6F0640Q33824203-229E7448-075B-477B-9BF9-8B96C5117E89Q33943421-AD06A2B8-5B12-4334-B338-E55A7C2B65D6Q34365210-41EEF81A-47F1-477D-AA70-81EF20E0DAEAQ34492884-65D78681-198C-4514-9FAC-183EFAC4769CQ34654408-9A6C3A99-714E-4597-87E8-F03AF8D9E5B1Q34657670-91F4428B-2CED-447C-85AC-A20B0DEFB702Q34781357-673B235A-B1BA-4B9E-97A1-92658CB63829Q34852951-F03C58F8-3657-45BC-8A54-82C00D0462DEQ35151544-CB83D63F-1B1E-4002-8AA4-4596A76DCBAAQ35364690-88CD5689-720E-4DE1-A185-AA6F28B56EB4Q35434274-0BA19CDD-62CE-48CB-A767-95E6B637A2F7Q35623817-243C796A-EE2F-4897-9A7B-B87AAA6ED781Q35898597-56009450-F655-4A91-854C-46D72713A3AAQ36000269-4C495F3D-09E0-4F93-AA67-22286D132831Q36026188-FB61029C-8DFE-4C6D-B231-0BD139378BAEQ36120023-22C49A5C-18B8-44BB-87E3-EA0A102B0301Q36353093-DD8EC193-D308-43D9-B4D0-5952D3AB622DQ36481954-FC023782-AEA2-42CF-8B58-293F46E275E7Q36491122-5E4BE88E-83CB-4B07-951C-71AB63F98F03Q36503084-9982126B-E235-49E8-90A2-B08F48C1D33DQ36698868-46FD98C1-9777-48E6-8583-224DB8E1EB2FQ36882732-A7C80CFA-1068-476D-B36C-F5041AE2962EQ37094986-C424493D-209F-4C98-A2FE-D0CCD4FC8C65Q37252270-1406D344-4F0E-4D5E-AABD-83A9E02A7378Q37269571-763F13A8-F8D1-435A-AAEB-D72027AAA7FDQ37404105-4CD00F80-25E9-4B58-B3B8-6A7B0E81BF97Q37579644-4896FB4A-195D-4D93-ABE3-0E31596EB500Q37699154-8D300C11-418B-420A-8DEE-091AB758BA06Q38109021-F75E8AC9-B057-4EAA-91DA-923AF9B0E0CBQ38868188-E8FF56B6-302B-4FFF-8F47-1812541138BBQ39129178-A7495790-7241-4516-A848-E8C269C6808AQ39813481-39BAAE61-83B6-4C4B-BFBD-E4359DD6335FQ39828582-DF7DAB3A-1EDD-4DBA-BC6F-80998BF4B463Q40141195-D28C1B31-2498-4D7D-823E-AAC2994A87FA
P2860
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@en
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@nl
type
label
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@en
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@nl
prefLabel
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@en
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@nl
P2093
P2860
P356
P1433
P1476
Distinctive activation pattern ...... itinib-sensitive EGFR mutants.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209159
P407
P577
2006-02-01T00:00:00Z
P5875
P6179
1048399518